Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32


The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.

Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D.

J Biol Chem. 2006 Sep 29;281(39):29105-19. Epub 2006 Aug 3.


Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.

Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H.

J Virol. 2006 Aug;80(15):7645-57.


Conformation of polypyrimidine tract binding protein in solution.

Petoukhov MV, Monie TP, Allain FH, Matthews S, Curry S, Svergun DI.

Structure. 2006 Jun;14(6):1021-7.


Modular structure of solubilized human apolipoprotein B-100. Low resolution model revealed by small angle neutron scattering.

Johs A, Hammel M, Waldner I, May RP, Laggner P, Prassl R.

J Biol Chem. 2006 Jul 14;281(28):19732-9. Epub 2006 May 16.


Monomeric APOBEC3G is catalytically active and has antiviral activity.

Opi S, Takeuchi H, Kao S, Khan MA, Miyagi E, Goila-Gaur R, Iwatani Y, Levin JG, Strebel K.

J Virol. 2006 May;80(10):4673-82.


APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.

Chelico L, Pham P, Calabrese P, Goodman MF.

Nat Struct Mol Biol. 2006 May;13(5):392-9. Epub 2006 Apr 23.


Structural basis of cellulosome efficiency explored by small angle X-ray scattering.

Hammel M, Fierobe HP, Czjzek M, Kurkal V, Smith JC, Bayer EA, Finet S, Receveur-Bréchot V.

J Biol Chem. 2005 Nov 18;280(46):38562-8. Epub 2005 Sep 12.


Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC.

Nature. 2005 May 5;435(7038):108-14. Epub 2005 Apr 13. Retraction in: Nature. 2010 Jul 8;466(7303):276.


Complementary function of the two catalytic domains of APOBEC3G.

Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR.

Virology. 2005 Mar 15;333(2):374-86.


Structure of human cytidine deaminase bound to a potent inhibitor.

Chung SJ, Fromme JC, Verdine GL.

J Med Chem. 2005 Feb 10;48(3):658-60.


Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM.

Curr Biol. 2005 Jan 26;15(2):166-70.


The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1.

Xie K, Sowden MP, Dance GS, Torelli AT, Smith HC, Wedekind JE.

Proc Natl Acad Sci U S A. 2004 May 25;101(21):8114-9. Epub 2004 May 17.


Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Yu Q, König R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR.

Nat Struct Mol Biol. 2004 May;11(5):435-42. Epub 2004 Apr 18.


HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Stopak K, de Noronha C, Yonemoto W, Greene WC.

Mol Cell. 2003 Sep;12(3):591-601.


Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR.

Cell. 2003 Jul 11;114(1):21-31.


DNA deamination mediates innate immunity to retroviral infection.

Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH.

Cell. 2003 Jun 13;113(6):803-9. Erratum in: Cell. 2004 Feb 20;116(4):629.


Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D.

Nature. 2003 Jul 3;424(6944):99-103. Epub 2003 May 28.

Items per page

Supplemental Content

Write to the Help Desk